Swedish Affibody and US Alexion Pharmaceuticals have announced a partnership to co-develop ABY-039 for rare Immunoglobulin G (IgG)-mediated autoimmune diseases. Under the terms of the agreement, Alexion will provide Affibody
Nordic Life Science
Lobsor Pharmaceuticals has been granted the US patent covering a pharmaceutical composition for the treatment of neurodegenerative disorders such as Parkinson’s disease. Lobsor has earlier received market authorization by the
Swedish Pilloxa is initiating a collaboration with the Scandinavian branch of Bayer and get the opportunity to introduce more people to their smart pillbox through Bayer’s network, both in Scandinavia and
Even premature babies carry anti-viral antibodies transferred from the mother, researchers at Karolinska Institutet in Sweden report in a paper on maternal antibodies in newborns, published in the journal Nature Medicine.
The company will present these preclinical data for the drug candidate ATOR-1017 at the 4th Annual Immuno-oncology Summit Europe, to be held in London on March 18-22, 2019. ATOR-1017 is a monoclonal
The Uppsala based company spoke at the Novel Antimicrobials and AMR Diagnostics Conference in Berlin, and stressed the importance of adopting new diagnostic approaches in the fight against antimicrobial resistance.
Sponsored content
Drug & Device development
The company will present these preclinical data for the drug candidate ATOR-1017 at the 4th Annual Immuno-oncology Summit Europe, to be held in London on March 18-22, 2019. ATOR-1017 is a monoclonal
The company has announced the dosing of the first patient in their first Phase 3 trial to evaluate dasiglucagon as a potential treatment option for children with CHI. “With the
LU Holding has founded MedBeat Sweden together with Erik Rask, MD at the University Hospital of Skåne. Erik Rask has developed a new kind of portable ECG device which is
The first patient has successfully been dosed in the company’s phase I study of ATOR-1015, its drug candidate in development for tumor-directed immunotherapy. ATOR-1015 is designed with properties that shall
The first cohort has been successfully dosed in the Phase 1, single ascending dose study to explore the pharmacokinetics and safety and tolerability of subcutaneous sevuparin injections in healthy volunteers
The last patient has been enrolled in the company’s study for the localized treatment of prostate cancer. The Phase IIb study will identify the optimal dose for Phase III and
Swedish Affibody and US Alexion Pharmaceuticals have announced a partnership to co-develop ABY-039 for rare Immunoglobulin G (IgG)-mediated autoimmune diseases. Under the terms of the agreement, Alexion will provide Affibody
Latest news
The company will present these preclinical data for the drug candidate ATOR-1017 at the 4th Annual Immuno-oncology Summit Europe, to be held in London on March 18-22, 2019. ATOR-1017 is a monoclonal
Our region is filled with life science activity. We take a closer look at what´s going in our Nordic cities when it comes to life science efforts, progress and challenges.
In focus – Nordic cities
Nordic Life Science
The latest clinical trials
The company will present these preclinical data for the drug candidate ATOR-1017 at the 4th Annual Immuno-oncology Summit Europe, to be held in London on March 18-22, 2019. ATOR-1017 is a monoclonal
The company has announced the dosing of the first patient in their first Phase 3 trial to evaluate dasiglucagon as a potential treatment option for children with CHI. “With the
The first patient has successfully been dosed in the company’s phase I study of ATOR-1015, its drug candidate in development for tumor-directed immunotherapy. ATOR-1015 is designed with properties that shall
The first cohort has been successfully dosed in the Phase 1, single ascending dose study to explore the pharmacokinetics and safety and tolerability of subcutaneous sevuparin injections in healthy volunteers
The last patient has been enrolled in the company’s study for the localized treatment of prostate cancer. The Phase IIb study will identify the optimal dose for Phase III and
Data from the company’s Phase II HORIZON study and Phase I/II ANCHOR study evaluating the company’s novel candidate melflufen have been selected as poster presentations at the 2019 American Association
The biopharmaceutical company announces the completion of enrollment in their Phase II proof-of-concept study of ABY-035 for moderate-to-severe psoriasis, AFFIRM-35. The double-blind, placebo controlled, Phase 2 proof-of-concept study (AFFIRM-35, NCT03591887)
AstraZeneca and MSD have announced positive results from the Phase III POLO trial. Results from the trial showed a statistically-significant and clinically-meaningful improvement in progression-free survival (PFS) with Lynparza (olaparib) vs. placebo.
The latest research news from the Nordic region
Science Article
Even premature babies carry anti-viral antibodies transferred from the mother, researchers at Karolinska Institutet in Sweden report in a paper on maternal antibodies in newborns, published in the journal Nature Medicine.
Aishe A. Sarshad at the Sahlgrenska Academy, the University of Gothenburg, receives the L’Oréal-Unesco For Women in Science Prize in Sweden for having identified a new mechanism for regulating gene expression
We asked the new Swedish Minister for Higher Education and Research about what can be done to encourage and support women in science. Today is International Women’s Day and you
Researchers at the University of Turku have developed an immunotherapeutic antibody therapy that re-educates macrophages to activate passivated cytotoxic T cells to kill cancer. In collaboration with Professor of Immunology
An international research team led by researchers at Karolinska Institutet report that bone growth in mice takes place in accordance with the same principles as when new cells are constantly
Two of the company’s researchers have been awarded Innovation Fund Denmark’s Innovator of the Year Award 2019. Focus for the Award is on ‘excellent and groundbreaking research which creates value